Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 10/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524505 | 1.00 | ROCK1 (0.39) | ROCK1NOTUMALOX12CACNA1GCACNA1H | |
| SCHEMBL3524506 | 1.00 | ROCK1 (0.39) | ROCK1NOTUMALOX12CACNA1GCACNA1H | |
| SCHEMBL10408965 | 0.77 | CRHBP (0.38) | ROCK1NOTUMDRD2DRD4LMNA | |
| SCHEMBL5038633 | 0.74 | GAA (0.36) | DRD2DRD4 | |
| SCHEMBL4257032 | 0.74 | GAA (0.36) | DRD2DRD4 | |
| SCHEMBL12404781 | 0.73 | BRD4 (0.35) | SIRT1 | |
| SCHEMBL3553533 | 0.73 | ALOX15 (0.43) | ROCK1NOTUMALOX12CACNA1GCACNA1H | |
| SCHEMBL3553536 | 0.73 | ALOX15 (0.43) | ROCK1NOTUMALOX12CACNA1GCACNA1H | |
| SCHEMBL8202698 | 0.73 | TAAR1 (0.54) | — | |
| SCHEMBL9501335 | 0.71 | CACNA1I (0.54) | ROCK1NOTUMALOX12CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2084152-A2 | SUBSTITUTED 4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | ROCK1 1612/4885NOTUM 4398/4885ALOX12 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.